Systemic and Tumor Th1 and Th2 Inflammatory Profile and Macrophages in Lung Cancer: Influence of Underlying Chronic Respiratory Disease-Reference-Cited by-同舟云学术

Systemic and Tumor Th1 and Th2 Inflammatory Profile and Macrophages in Lung Cancer: Influence of Underlying Chronic Respiratory Disease

Published:2017-02 Issue:2 Volume:12 Page:235-248
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Mateu-Jimenez Mercè,Curull Víctor,Pijuan Lara,Sánchez-Font Albert,Rivera-Ramos Hugo,Rodríguez-Fuster Alberto,Aguiló Rafael,Gea Joaquim,Barreiro Esther

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference46 articles.

1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008;Ferlay;Int J Cancer,2010

2. Spanish guideline for COPD (GesEPOC). Update 2014;Miravitlles;Arch Bronconeumol,2014

3. What was the impact of the Spanish COPD guidelines (GesEPOC) and how can they be improved?;Miravitlles;Arch Bronconeumol,2016

4. Trends and characteristics of young non-small cell lung cancer patients in the United States;Thomas;Front Oncol,2015

5. Refining the treatment of NSCLC according to histological and molecular subtypes;Thomas;Nat Rev Clin Oncol,2015

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive molecular characterization of long-term glioblastoma survivors;Cancer Letters;2024-07

2. Effectiveness of Immunotherapy in Non-Small Cell Lung Cancer Patients with a Diagnosis of COPD: Is This a Hidden Prognosticator for Survival and a Risk Factor for Immune-Related Adverse Events?;Cancers;2024-03-22

3. A review of natural products targeting tumor immune microenvironments for the treatment of lung cancer;Frontiers in Immunology;2024-02-01

4. A Comprehensive Exploration of Metabolism and Tumor Microenvironment and Immunotherapy Response: Evidence From Large Populations in Non-small Cell Lung Cancer;Current Cancer Drug Targets;2024-01

5. Single-cell profiling reveals the heterogeneity of NK cells during anti-PD-1 therapy in non-small-cell lung cancer;International Immunopharmacology;2023-11